Build your own
evidence
Good Medicine is based on proof, but real conditions can make the difference. Let us help you build your own evidence and provide the best care for your patients.
Log in
Please enter your ID
| Ileana Hocking | Ileana |
| Ken Bullock | Ken |
| The Heart Beat Clinic | heartbeat |
| Estudio Cohorte | COHORTE |
| Ventas | ventas |
| Demo Sales | demosales |
| Demo Customer | democustomer |
| Newtech Italia | Newtech |
| Medsafe Latam | Medsafe |
| Novamedical Portugal | Novamedical |
| cudbein Brazil | cudbein |
| UKB Registry | ukb |
| Todd Whetsel | Todd |
Study of Syncope and Rare Palpitations
Hospital Virgen de los Lirios. Alcoy (Spain). Gómez Pastor et al. Sociedad Valenciana de Cardiología
RESULTS
42% of diagnostic yield in patients with syncopal episodes. Syncope of cardiogenic origin in 15% of patients and 27% with the exclusion of cardiogenic syncope *.
PROTOCOL
CONCLUSIONS
“The incorporation of Nuubo into the diagnostic algorithm of cardiogenic syncope represents a step forward in the management of this disease because it provides remarkable diagnostic efficacy at a lower cost compared to more classic options. 73% Reduction the use of ILR.”
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope
Class IIa
To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, the external cardiac monitors can be useful.
Although the diagnostic yield of an external loop recorder may be lower than that of an implantable cardiac monitor, the non-invasive strategy is reasonable as a first approach.
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Class I
Ambulatory electrocardiograhic monitoring is useful to evaluate whether symptoms, including palpitations, presyncope, or syncope, are caused by ventricular arrhythmias.
Atrial Fibrillation Detection After Stroke
Wearable Holter for AF detection in high risk patients after cryptogenic stroke (CRYPTO-AF).Pagola, J. et al. International Journal of Cardiology, Volume 251
RESULTS
21% of patients had an Atrial Fibrillation episode detected with Nuubo in the 30 days after the cryptogenic stroke*.
PROTOCOL
CONCLUSIONS
“Following our results, prolonged monitoring should be started immediately and maintained the first 4 weeks after stroke onset avoiding any delay and any gap. 28-day Holter monitoring from the acute phase of the stroke was feasible with Nuubo”
AHA / ASA GUIDELINE 2014 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Class IIa
For patients who have experienced an acute ischemic stroke or TIA with no other apparent cause, prolonged rhythm monitoring (≈30 days) for AF is reasonable within 6 months of the index event.
CRYPTO-AF and THUNDER
Dr. Pagola
11 Min
Using.nuubo.com is propriety of Nuubo.
www.nuubo.com